A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Presented as SABCS 2019.
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.
ESMO has announced that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
We are pleased to inform you that an exploratory analysis of the randomized phase III GrparOcto trial has been published in Cancer
GBG Forschungs GmbHMartin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd